Chronic kidney disease (CKD) is an important public health issue. The prevalence of CKD in the general populations of various countries is 10-12% and this proportion increases considerably with age 1,2 . Despite progress in the development of treatment strategies to improve outcomes, CKD is associated with high morbidity and mortality, mainly owing to cardiovascular complications [3] [4] [5] . CKD shares several pathophysiological processes with ageing and is a model of premature senescence 6, 7 . Disorders of mineral metabolism have a central role in the pathophysiology of CKD, and their importance in the ageing process is increasingly recognized 6, 7 . In addition, alterations of mineral metabolism are associated with increased risk of mortality and cardiovascular disease (CVD) in patients with CKD 8 and in the general population 9, 10 . Tissue mineralization is tightly regulated by several stimulatory and inhibitory proteins such as alkaline phosphatase (ALP, also known as orthophosphoricmonoester phosphohydrolase, alkaline optimum). Both CKD and ageing are characterized by active dysregulation of the intricate balance between these proteins 6, 7 . ALP stimulates mineralization mainly through modulation of the balance between inorganic phosphate (P i ) and inorganic pyrophosphate (PP i ) and also has a role in cardiovascular remodelling. In addition, ALP is a well-recognized biomarker of renal osteo dystrophy and a biomarker and risk factor for increased mortality in patients with CKD 11 and in the general population 9 . In this Review we discuss the clinical relevance of ALP, and in particular that of bone-specific ALP (BALP) and intestinal-type ALP (IALP), in CVD and mortality, including their roles as putative targets for the treatment and prevention of cardiovascular complications in patients with CKD.
. CKD shares several pathophysiological processes with ageing and is a model of premature senescence 6, 7 . Disorders of mineral metabolism have a central role in the pathophysiology of CKD, and their importance in the ageing process is increasingly recognized 6, 7 . In addition, alterations of mineral metabolism are associated with increased risk of mortality and cardiovascular disease (CVD) in patients with CKD 8 and in the general population 9, 10 . Tissue mineralization is tightly regulated by several stimulatory and inhibitory proteins such as alkaline phosphatase (ALP, also known as orthophosphoricmonoester phosphohydrolase, alkaline optimum). Both CKD and ageing are characterized by active dysregulation of the intricate balance between these proteins 6, 7 . ALP stimulates mineralization mainly through modulation of the balance between inorganic phosphate (P i ) and inorganic pyrophosphate (PP i ) and also has a role in cardiovascular remodelling. In addition, ALP is a well-recognized biomarker of renal osteo dystrophy and a biomarker and risk factor for increased mortality in patients with CKD 11 and in the general population 9 . In this Review we discuss the clinical relevance of ALP, and in particular that of bone-specific ALP (BALP) and intestinal-type ALP (IALP), in CVD and mortality, including their roles as putative targets for the treatment and prevention of cardiovascular complications in patients with CKD.
ALP biology: isozymes and isoforms
In this Review, we use the acronym ALP as a collective term for all isozymes and isoforms of ALP and when discussing studies that used unspecific methods for the determination of ALP. In humans, four ALP isozymes exist: alkaline phosphatase, tissue-nonspecific isozyme (TNALP, also known as TNSALP, TNAP, AP-TNAP, and alkaline phosphatase liver/bone/kidney); alkaline phosphatase, intestinal-type (IALP, also known as IAP); alkaline phosphatase, placental-type (PALP, also 
Isozymes
Proteins encoded by separate genes with similar catalytic specificity but different primary structure.
Isoforms
Variations of a protein that arise from single nucleotide polymorphisms, differential splicing of mRNA, or posttranslational modifications such as glycosylation.
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Abstract | Cardiovascular disease is the main cause of early death in the settings of chronic kidney disease (CKD), type 2 diabetes mellitus (T2DM), and ageing. Cardiovascular events can be caused by an imbalance between promoters and inhibitors of mineralization, which leads to vascular calcification. This process is akin to skeletal mineralization, which is carefully regulated and in which isozymes of alkaline phosphatase (ALP) have a crucial role. Four genes encode ALP isozymes in humans. Intestinal, placental and germ cell ALPs are tissue-specific, whereas the tissue-nonspecific isozyme of ALP (TNALP) is present in several tissues, including bone, liver and kidney. TNALP has a pivotal role in bone calcification. Experimental overexpression of TNALP in the vasculature is sufficient to induce vascular calcification, cardiac hypertrophy and premature death, mimicking the cardiovascular phenotype often found in CKD and T2DM. Intestinal ALP contributes to the gut mucosal defence and intestinal and liver ALPs might contribute to the acute inflammatory response to endogenous or pathogenic stimuli. Here we review novel mechanisms that link ALP to vascular calcification, inflammation, and endothelial dysfunction in kidney and cardiovascular diseases. We also discuss new drugs that target ALP, which have the potential to improve cardiovascular outcomes without inhibiting skeletal mineralization.
. In serum, BALP and liver TNALP are the most abundant isoforms, comprising more than 90% of total serum ALP activity in a 1:1 ratio 13 . These organ-specific isoforms of TNALP differ only in their levels of post-translational glycosylation 14 , which affects their enzymatic activity 15, 16 . BALP and liver TNALP have five putative N-glycosylation sites, which are all located around the catalytic site [17] [18] [19] . In addition, TNALP contains a magnesium ion and two zinc ions as cofactors near the active centre as well as calcium in a specific calcium-binding site 20 . Variations in the concentrations of these metals can also influence ALP activity [21] [22] [23] . All ALP isozymes function as ectoenzymes 24, 25 and are attached to the outer cell membrane by a glycosylphosphatidylinositol (GPI) anchor 26, 27 . Circulating levels of ALP activity reflect levels of ALP activity in tissues 28 , but the exact mechanisms of ALP release into the general circulation remain unclear. Some studies suggested that GPIspecific phospholipase D converts membrane-anchored ALPs to the anchorless forms found in serum 28, 29 . Three different BALP isoforms, B/I (bone and intestinal), B1 and B2, can be separated and quantified in human serum by weak anion-exchange high-performance liquid chromatography 14, 30 . Of note, the B/I fraction is not pure BALP isoform as it co-elutes with the small fraction of IALP isozyme present in the general circulation 14 . The B/I fraction includes ~70% BALP isoform activity and ~30% IALP isozyme activity, and comprises only 6% of the entire BALP activity in serum 28 . The three BALP isoforms (B/I, B1 and B2) are present in the serum and bone in healthy adults 31 , children and adolescents 32 , and in patients with various metabolic bone diseases 13, 33, 34 . In addition, a fourth BALP isoform, B1x, is present in extracts of human bone tissue 28, 35 and exclusively in the serum of patients with different stages of CKD 31, [36] [37] [38] , in whom it is a marker of low bone turnover 38 . All BALP isoforms, including B1x, are also expressed in vascular smooth muscle cells (VSMCs), the calcification of which is associated with a strong increase in BALP activity level 39 . In particular, increased B1x, B/I and B2 activity could be associated with phosphate-induced vascular calcification 40 . In bone, the B1:B2 ratio differs between cortical sites (~1.7) and trabecular sites (~0.7) 35 . Intriguingly, this ratio was higher in serum samples from patients on dialysis than in those from healthy controls, which could be the result of higher cortical bone turnover in these patients, associated with hyperparathyroidism 31 .
ALP function Bone and vascular calcification
Mineralizing cell types. Physiological bone and teeth mineralization is orchestrated by cells of mesenchymal origin, such as hypertrophic chondrocytes, odontoblasts and osteoblasts 41, 42 . Vascular calcification is associated with osteochondrogenic transformation of vascular cells of mesenchymal origin, such as myocytes, pericytes or fibroblasts 43 . Macrophage-like cells with mineralizing potential have also been described in the vascular wall 44 ; whether these cells are monocytic macrophages that migrated from the circulation or VSMCs that adopted a macrophage-like phenotype is unclear 45 . A 2016 genetic fate tracing study identified a novel mechanism of vascular calcification: adventitial Gli1 + mesenchymal stem cell-like cells migrate into the media and neointima during atherosclerosis and arteriosclerosis in ApoE −/− mice with CKD 46 . Genetic ablation of Gli1 + cells before the induction of kidney injury reduced the severity of vascular calcification, suggesting that Gli1 + cells could be a major source of osteoblast-like cells during calcification in the media and intima.
Mechanisms of mineralization. Independent of the cell type involved, bone and vascular mineralization are associated with the release of matrix vesicles, which are a nidus of extracellular matrix mineralization 43 ( FIG. 1) . Two types of secreted matrix vesicles have been described in calcifying VSMCs: non-calcifying vesicles, which contain calcification inhibitors such as fetuin A, and matrix-bound vesicles with increased calcification potential, which are rich in membrane-bound TNALP 47 . BALP is responsible for the propagation of tissue mineralization and is expressed in osteoblasts, chondrocytes, and other mineralization competent cells, such as calcifying VSMCs 48 . Although calcifying human
• Circulating alkaline phosphatase (ALP) is a robust and independent predictor of all-cause mortality in the general population and in patients with chronic kidney disease (CKD) • Tissue-nonspecific ALP (TNALP) is the most abundant ALP isozyme in the body, comprising >90% of circulating ALP; functional differences between bone ALP (BALP) and liver TNALP are the result of post-translational glycosylation • BALP promotes tissue mineralization by inactivating calcification inhibitors and by supplying phosphate • Liver ALP and intestinal ALP (IALP) contribute to the immune response through dephosphorylation of circulating endotoxins • Modulation of ALP is a potential novel treatment strategy that might reduce vascular calcification and improve cardiovascular outcomes in patients with CKD or diabetes mellitus type 2
VSMCs exclusively express BALP in vitro 40 , most studies in human and animal models do not specify the measured TNALP isoform, which does not exclude that other isoforms could be involved in vascular calcification. The highest concentration of BALP is found in matrix vesicles shed by VSMCs 49 . Loading of BALP onto matrix vesicles is an active process, which can be modulated by pro-calcific stimuli such as the inhibition of autophagy in a P i -rich milieu 50 . Autophagy of damaged cellular components is a defence mechanism that protects VSMCs from P i -induced oxidative stress. Inhibition of autophagy stimulates the release of pro-calcific matrix vesicles with increased ALP activity 50 . The proteinsorting peptide sortilin is involved in loading ALPs on matrix vesicles during vascular calcification in mice 51 . Interestingly, sortilin deficiency in mice reduces vascular calcification but does not affect bone mineralization 51 . The predominant role of BALP during mineralization is the inactivation of inhibitory polyphosphates 52 , most importantly the main autocrine calcification inhibitor PP i 53, 54 . ALPs are also speculated to inactivate the calcification inhibitor osteopontin through dephosphorylation 55 and a 2017 study showed that human BALP can suppress the inhibitory effect of osteopontin on in vitro mineralization 56 . In addition, ALPs generate P i , which is the substrate of mineralization, by hydrolysation of organic phosphate esters 57 . The P i :PP i ratio has become increasingly recognized as a central determinant of tissue mineralization as hydroxyapatite crystals form and grow within matrix vesicles and in the extracellular matrix when P i and calcium concentrations surpass their solubility product, whereas PP i hinders this process by attaching to the surface of hydroxyapatite crystals [58] [59] [60] . In the extracellular matrix, this balance is maintained by membrane-bound enzymes, mainly ectonucleotide pyrophos phatase/phosphodiesterase family member 1 (E-NPP 1, also known as NPP1 and plasma-cell membrane glycoprotein PC-1) and BALP 48 . The expression of these enzymes is regulated by hormones that regulate mineral metabolism, such as fibroblast growth factor 23 (REF. 61 ) and 1,25-dihydroxyvitamin D 62 . A local disturbance of the P i :PP i ratio in the vascular wall can promote calcification in spite of normal serum phosphate levels 63 . Thus, the elevated ALP activity found in syndromes with accelerated vascular calcification and premature senescence such as CKD 64, 65 , diabetic arterial media calcification 66, 67 , arterial calcification due to 5ʹ-nucleotidase (also known as CD73) deficiency 68 , and Huntington-Gilford Progeria Syndrome 69 , could contribute to a local pro-calcific environment in the vascular wall by decreasing PP i concentrations. The importance of TNALP in inducing vascular wall calcification was convincingly shown in mice with genetically modified TNALP expression in vascular wall layers. TNALP overexpression in VSMCs 70 and in endothelial cells 71 both resulted in ectopic calcification.
Parathyroid hormone (PTH) has a pivotal role in the regulation of bone turnover, but its involvement in vascular calcification is less clear than that of ALP 72 . Experimental studies suggest that increased levels of PTH are associated with vascular calcification 72 . However, in uraemic rats, hyperparathyroidism is only associated with vascular calcification in the presence of hyperphosphataemia 73 . Thus, PTH might not exert a direct effect on vascular cells. Instead, PTH-induced release of phosphate from bone, with subsequent hyperphosphataemia, could be responsible for the association between increased PTH and vascular calcification. Following the recommended target range for PTH levels does not improve the risk of cardiovascular events or mortality in patients with CKD 74, 75 . A meta-analysis showed that higher serum phosphate levels, but not serum calcium or PTH levels, were associated with all-cause mortality and CVD 76 , whereas in some clinical studies low PTH levels combined with high BALP levels were more strongly associated with mortality 11 and CVD 77 than high serum levels of PTH.
ALP activity in disease

Modulation of inflammation
Several associative studies on serum levels of components of mineral metabolism and inflammatory markers indicate a relationship between systemic inflammation and serum ALP activity [78] [79] [80] [81] (FIG. 2a) . In some Also known as germ cell alkaline phosphatase.
Metabolic syndrome
Array of conditions -raised blood pressure, dyslipidaemia (raised triglycerides and lowered HDL cholesterol), raised fasting glucose, and increased waist circumference -that increase the risk of cardiovascular disease and type 2 diabetes mellitus.
observational studies levels of C-reactive protein (CRP) modulated the association of serum ALP levels with mortality or CVD in the general population [82] [83] [84] . Experimental studies in human osteoblasts and VSMCs suggested a direct association between the presence of mediators of inflammation in culture media and the induction of ALP activity in mineralizing cells 39, [85] [86] [87] . For example, CRP decreased TNALP activity and mineralization in cultured osteoblasts, which was associated with decreased expression of the mineralizing transcription factor RUNX2 85 , whereas TNF stimulated mineralization and ALP expression in osteoblasts independent of RUNX2 (REF. 86 ). TNF also stimulated BALP activity and calcium deposition in VSMCs 39 . Autocrine TNF signalling has an important role in VSMC calcification 87 . TNALP is not only expressed by mineralization competent cells and its expression in activated neutrophils might contribute to the inactivation of endotoxins in the circulation 88 .
The role of purinergic signalling in the regulation of the immune response is also an evolving area of research. Extracellular ATP induces proinflammatory responses via P2Y receptors, whereas adenosine can have the opposite effect, conveyed by P1 receptors 89, 90 . The conversion of proinflammatory ATP to anti-inflammatory adenosine is catalysed by membrane-bound and soluble ectonucleotidases, mainly 5ʹ-nucleotidase and ectonucleoside triphosphate diphosphohydrolase 1 (also known as CD39), but also by ALPs 90 . Thus, increased ALP expression could be a cellular response to inflammatory stimuli. In this context, IALP 91 , TNALP in vascular endothelial cells 92 and leucocytes 88 , and potentially, liver isoforms of TNALP 93 , could contribute to the increased levels of serum ALP activity found in acute sepsis and other acute inflammatory conditions (see below). A 2015 study proposed a potential involvement of purinergic signalling in diseases associated with chronic inflammation, such as atherosclerosis 94 , suggesting a hypothetical role for ALPs as part of a vascular defence mechanism in CVD. However, the association of reduced nucleotide signalling via the P2Y receptor with increased arterial intimal and VSMC calcification in P2Y 2 R −/− mice 95 , as well as the accelerated arterial calcification seen in mice that overexpress TNALP in endothelial cells 71 and VSMCs 70 , raise concerns about putative therapeutic interventions that aim to increase ALP activity for the long-term treatment of CVD.
IALP, inflammation and the metabolic syndrome
IALP is expressed and secreted by intestinal epithelial cells (especially in the duodenum), but is also biologically active in the serum 91 . The expression of IALP is regulated by various nutritional and inflammatory factors 96 . The effects of IALP activity in inflammatory conditions and in the metabolic syndrome is an emerging field of clinical research as this ALP isozyme has important functions in gut mucosal defence. IALP maintains intestinal homeostasis by inactivating bacterial endotoxins such as lipo polysaccharide (LPS), regulating intestinal lipid absorption, eliminating toxic nucleotides and determining the composition of the intestinal microbiome 91 (FIG. 2b) . Nature Reviews | Nephrology Studies of the isozyme composition of serum ALP revealed that levels of IALP activity are considerably increased in patients with CKD [97] [98] [99] [100] [101] . CKD might thus be a suitable model for further clinical and experimental studies on the biological significance of IALP. Given the important role of bacterial endotoxins 102 , intestinal dysbiosis and barrier dysfunction 103 in uraemic inflammation and associated morbidity and mortality, studies of the function of IALP in mucosal defence of the uraemic gut and in metabolic alterations certainly deserve more attention.
Patients with CKD have profound alterations in the gut environment, such as shifts in microbial composition and increased blood levels of gut microorganism-derived metabolites 104 . Interestingly, faeces of IALP-knockout mice contain fewer and less diverse bacteria than those of wild-type mice; these effects are reversed by IALP supplementation 105 . Patients with CKD can also suffer from antibiotic-associated diarrhoea caused by infection with Clostridium difficile, which is a major clinical problem 106 . IALP administration prevented antibiotic-induced susceptibility to enteric pathogens in mice 107 . Chronic endotoxaemia, systemic low-grade inflammation, gut dysbiosis and local intestinal inflammation are important contributors of the metabolic syndrome, which is a commonly associated with CKD 108 . IALP-deficient mice had increased circulating levels of endotoxins, central obesity, dyslipidemia and insulin resistance 109 , suggesting that IALP could have a central role in the development of the metabolic syndrome. Oral supplementation with IALP could prevent and reverse the development of several symptoms of the metabolic syndrome in these animals. A 2015 study showed that patients with type 2 diabetes mellitus (T2DM) have lower faecal levels of IALP activity than do healthy controls, and that higher faecal IALP activity might be protective against T2DM, independent of obesity 110 .
Endothelial dysfunction
The importance of endothelial ALP for vascular health is increasingly recognized. TNALP is highly expressed in the endothelial cells of cardiac 111 and brain microvessels and contributes to the function of the bloodbrain barrier (BBB) by regulating transcellular transport and organization of the cytoskeleton 112 . Similar to senescence-induced TNALP expression and calcification in VSMCs 113 , vascular endothelial cell and pericyte senescence contributes to BBB breakdown 114 . To what extent this process involves TNALP in brain microvessels has yet to be determined.
ALP might also participate in the anti-inflammatory function of endothelial barriers 115 . According to this hypothesis, increased release of membrane-bound endothelial ALP into the circulation caused by increased activity of phospholipase C or D could result in decreased cellular ALP levels and thereby contribute to BBB dysfunction in neurodegenerative diseases such as Alzheimer disease, owing to disturbed transcellular transport. Whether ALP is involved in dysfunction of the endothelial barrier, disturbs BBB function in CKD, or causes arterial stiffness or proteinuria in the kidney and leads to CKD progression has yet to be elucidated. Increased levels of serum ALP are also associated with endothelial dysfunction in hypertensive individuals without CKD 116 . Experimental data suggest that the induction of vascular ALP activity by oxidative stress and the consequent promotion of vascular calcification is a possible underlying mechanism [117] [118] [119] [120] . The increase in the mortality risk associated with high levels of TNALP caused by oxidative stress (assessed by γ-glutamyltransferase levels) in patients with CKD gives some clinical support to this hypothesis 121 . In addition, overexpression of endothelial TNALP is sufficient to induce arterial medial calcification and vascular stiffening in mice 71 , underscoring the importance of endothelial ALP activity in vascular disease.
Proteinuria
In patients with type 1 diabetes mellitus (T1DM), an increase in circulating levels of ALP is associated with glomerular hyperfiltration, proteinuria and CKD progression in the early stages of diabetic nephropathy 122, 123 . These studies did not characterize the origin of the increased levels of serum ALP. Although the association was independent of blood pressure, a contribution of oxidative stress levels, inflammation or vascular calcification (as discussed above) cannot be ruled out, even in the early stages of the disease. In addition, increased levels of urinary TNALP, presumably derived from tubular cells, have long been suggested to be a marker of kidney disease 124 . TNALP released from tubular cells damaged by glomerular hyperfiltration 125, 126 could contribute to increased levels of urinary ALP in patients in the early stages of diabetic nephropathy. Furthermore, glomerular endothelial and mesangial cells 127 , epithelial cells in the Bowman capsule 128 , and cells of the juxtra glomerular apparatus 129 express ALP in physiological conditions (albeit at lower levels than do tubular cells); release of ALP from these cells could further elevate urinary ALP levels in patients with glomerular hyperfiltration. The biological function of ALP in the kidney is unknown and to what extent renal isoforms of TNALP contribute to circulating ALP activities in the early stages of diabetic nephropathy is unclear; however, kidney TNALP seems to be linked to PP i metabolism and LPS detoxification 127 . Of note, patients with hypophosphatasia owing to loss-of-function mutations in ALPL, which encodes TNALP 130 , do not usually develop kidney disease.
Cardiovascular disease
General population. In a 2014 meta-analysis, Li and colleagues investigated the involvement of ALP in CVD in non-CKD populations 9 . They found that ALP levels were independently associated with CVD death; however, the association between ALP levels and non-fatal CVD events or coronary heart disease became nonsignificant after full adjustment for confounders, including inflammation. In a second meta-analysis, also published in 2014, baseline levels of ALP were independently associated with prospective CVD risk in four studies 131 . Although inflammation was accounted for, the researchers did not specify the direct effect of inflammation on the association between ALP levels and different types of CVD. In 2015, an independent association was reported between serum ALP levels and CVD during a 10-year prospective follow-up of 6,974 participants aged 28-75 years without pre-existing CVD 82 . This associ ation was weak but significant, even after adjustment for CRP levels. ALP levels were not associated with stroke and the association with ischaemic heart disease disappeared after several adjustments. Increased total ALP levels were associated with acute myocardial infarction (AMI) in a case-control study of patients who had experienced a first AMI 132 , and further characterization revealed that BALP was the main source of the increased total ALP activity. In another prospective study of patients with coronary heart disease undergoing coronary stent implantation, high levels of total ALP activity predicted all-cause mortality, AMI and stent thrombosis 104 . The latter was speculated to be an effect of reduced endothelialisation in calcified coronary arteries as ALP levels were independently associated with coronary calcification in this study. Although the combination of elevated CRP and ALP levels increased hazard ratios for all-cause mortality, the correlation between ALP and CRP levels was small, and the association between ALP and cardiovascular events was not influenced by CRP levels 133 . Thus, although evidence of an association between ALP levels and CVD incidence exists, associ ations can vary depending on the population studied and the type of CVD. Inflammation modulated the association of ALP levels with CVD incidence in some, but not all studies, suggesting that ALP could be used as a novel predictor of cardiovascular mortality and morbidity in the non-CKD population.
Patients with CKD.
Vascular calcification is a widespread feature of the uraemic phenotype and is frequently coupled to premature CVD and increased mortality 2 . We have identified high serum ALP levels as a strong risk factor for coronary calcification in patients on maintenance haemodialysis, independent of inflammation and traditional cardiovascular risk factors 134 . In a prospective study of 135 patients with stage 1-5 CKD not on dialysis, cardiovascular events were positively associated with circulating BALP levels and negatively associated with circulating levels of tartrate-resistant acid phosphatase isoform type 5b (TRAP 5b, also known as TRACP and TR-AP) 77 ; however, no association between cardiovascular events and PTH levels was observed. TRAP 5b is mainly expressed by osteoclasts, which drive bone resorption, and is expressed at low levels outside the bone. As non-bone-derived TRAP 5b is unlikely to contribute substantially to circulating levels, low serum levels of TRAP 5b indicate reduced bone turnover 77 . BALP expression, on the other hand, can be upregulated in calcifying arteries, as discussed above. Thus, the researchers suggested that the increased levels of circulating BALP in patients with CKD were derived from calcified arteries rather than from bone. Several reports have provided direct evidence for an association between low bone turnover and accelerated vascular calcification 135, 136 . Decreased bone turnover reduces the capacity to incorporate ingested calcium into bone, thereby providing a possible substrate for vascular calcification 137, 138 . In mild CKD, high circulating levels of BALP are also independently associated with carotid enlargement, an early sign of arterial disease 139 . Further evidence supporting a role of ALP in uraemic vascular calcification was provided by a study in which upregulation of ALP activity in the vascular wall by experimental uraemia was associated with reduced levels of circulating PP i 140 , which is in accordance with previous descriptions of reduced PP i levels in patients with CKD 141 . Interestingly, experimental treatment with systemically administered PP i can inhibit uraemic vascular calcification 142 . The different enzymatic activities of BALP isoforms towards PP i and other substrates 16 suggest functional differences among isoforms in the multifaceted process of vascular calcification.
ALP and mortality
General population. The focus on ALP as an emerging risk factor for mortality in different populations is novel. A 2014 meta-analysis investigated the association between total levels of ALP and mortality in the general population 131 . In this study, patients in the highest tertile of serum ALP levels experienced a 38% higher risk of all-cause mortality than patients in the lowest tertile. Li et al. also found a positive correlation between ALP and all-cause and cardiovascular mortality independent of kidney function and pre-existing CVD (relative risk of all-cause mortality 1.57 for patients with ALP levels >90 U/l, compared with patients with ALP levels <70 U/l) 9 . A 2009 study showed that increased levels of ALP and phosphate are independent risk factors for all-cause and cardiovascular mortality in the general popu lation 143 . Individuals with a combination of increased ALP and phosphate levels had the highest mortality risk. In a large cohort study, high ALP levels were associated with CRP levels and mortality in the general North-American population, independent of liver function 83 . These associations were not found for BALP levels and the researchers speculated that the associations of ALP levels with CRP levels and mortality were caused by a TNALP isoform produced by activated neutrophils. However, this study was flawed by the use of different methods for the determination of serum BALP activities and the change of age limits for inclusion during the recruitment period. Furthermore, the researchers speculated that the study lacked power owing to low mortality rates. A different study reported that total levels of ALP were associated with all-cause mortality independent of classical cardiovascular risk factors and CRP levels 133 . Taken together, these studies identify ALP as an independent predictor of mortality in the general population. CRP levels might have a modulatory effect on the association of ALP activity with mortality in CVD, but in the majority of studies the association of ALP with mortality was independent of inflammation.
Patients with CKD. ALP and, more specifically, BALP have been recognized as biomarkers of renal osteodystrophy for decades 75 . Additionally, numerous cross-sectional and longitudinal studies have shown correlations between high ALP levels and mortality in patients with CKD 121,144-167 (TABLES 2-4). Notably, these associations were independent of several confounders, including phosphate, calcium, PTH, vitamin D treatment, protein energy wasting, liver function and inflammation (TABLES 2-4). In prevalent and incident patients on dialysis, ALP levels <100 U/l were not associated with any survival benefit 145, 158 . In our opinion, this finding could indicate that low circulating ALP levels are associated with low bone turnover (adynamic bone), which is a risk factor for vascular calcification 135 and mortality 138 . In a longitudinal study, the association between increasing levels of ALP over time and mortality depended on baseline ALP levels in patients on incident dialysis 158 . Patients with baseline ALP levels >120 U/l had increased mortality, independent of ALP trends over time. In patients with baseline ALP levels of 80-120 U/l increasing ALP levels over time were associated with increased mortality; stable or decreasing ALP levels did not affect mortality. In patients with ALP <80 U/l, neither increasing nor decreasing trends were associated with mortality. Our data indicate that ALP levels <120 U/l confer a survival benefit 144, 145, 148, 151, 159, 167 ; however, randomized prospective trials are needed to evaluate target ALP levels for the prevention of cardiovascular events and all-cause mortality.
We showed that pre-transplantation levels of ALP, but not PTH, predicted mortality after kidney transplantation in a large cohort of patients undergoing dialysis 159 . A prospective study of prevalent kidney transplant recipients showed that γ-glutamyltransferase and ALP levels, but not BALP levels, were independently associated with mortality 160 . The researchers speculated that these associations might be related to vascular oxidative stress, as indicated by the presence of the γ-glutamyltransferase circulating marker. Oxidative stress is associated with CVD and can induce the expression of ALP in vascular cells (see above). This study did not correct for liver function tests; however, separate analyses of these tests did not show any association between liver function and mortality. In addition, total levels of ALP are associated with mortality 118, 119, 127, 138 and CKD progression 118 in pre-dialysis patients with stage 3-4 CKD.
Taken together, these studies show that ALP levels greater than or equal to the upper reference interval limit were associated with high mortality despite the use of various routine laboratory methods for the determination of serum ALP activity. Serum ALP and BALP activities are reported in a variety of units and a wide range of numerical values, which could be due to the fact that reaction conditions 30 (substrate type and concentration; buffer type, concentration, and pH; reaction temperature) influence ALP activity levels differently among ALP isozymes and isoforms 168, 169 . This methodological variability might explain why expert committees have not yet endorsed definite target levels for ALP 170 . Introduce future target levels for ALP in relation to the upper reference interval limit instead of fixed values in order to harmonize treatment strategies globally might be preferable. 
BALP and mortality
The use of BALP levels in clinical practice is less common than that of total ALP levels and data on the association of BALP levels with mortality in the general population are sparse. As mentioned above, a large North American observational study could not establish an associ ation between BALP levels and mortality in the general population or in patients with mild CKD 83 ; however, this study had several shortcomings and its findings are unconfirmed. Other studies reported an independent association between BALP levels and mortality in patients with more advanced stages of CKD 11, 171 . A stronger association between short-term mortality and BALP levels, compared to total ALP levels, was described in 800 patients undergoing dialysis 11 . This study also found a somewhat weaker association between BALP and long-term mortality. Patients with low PTH and BALP levels had an increased risk of short-term mortality and signs of protein-energy wasting, compared to patients with low PTH and high BALP levels 11 . In male Japanese patients on dialysis, BALP levels were independently associated with all-cause mortality at 70 months 171 . No such associ ation was found for the levels of PTH or other metabolic bone markers. In addition, patients had a lower biological variability in BALP levels than in the levels of PTH or other metabolic bone markers 171 , which was consistent with findings from other studies 172, 173 . High levels of total ALP and BALP were associated with high mortality in patients undergoing dialysis 157 ; however, the association of BALP levels with mortality was no longer significant when total ALP levels was omitted from the Cox regression analysis. On the other hand, the lowest individual BALP levels during a 3-year period were associated with improved survival. A stronger association of ALP or BALP levels with short-term mortality than with long-term mortality in patients with CKD has been shown in several studies 11, 149 , which suggests underlying pathophysiologic processes with high progression rates. BALP is a promising predictor of mortality, especially in patients with CKD. The development of novel analytic methods based on levels of BALP isoforms will further improve the diagnostic accuracy of BALP levels in bone disease and CVD.
Treatment strategies targeting ALP Established treatment regimens for mineral and bone disorders in CKD, such as administration of vitamin D receptor activators, cinacalcet or parathyroidectomy, target serum levels of PTH, calcium and phosphate 170 . Although these strategies can also influence ALP levels (FIG. 2a) , no specific target levels of ALP have yet been proposed and no treatment strategy directed at lowering ALP levels has been established. ALP levels are a superior target than PTH levels for the treatment of disturbed bone turnover in CKD 75, 174, 175 . In addition, serum ALP and BALP levels predict cardiovascular complications and mortality and these enzymes are essential regulators of ectopic mineralization. These findings point towards a role of TNALP and, more specifically BALP, in the pathophysiology of CVD. Efforts are, therefore, underway to characterize ALP levels as a promising treatment target for the prevention of these severe complications. Such novel therapies have the potential to reduce the contribution of extra-skeletally generated ALP to increased cardiovascular risk in CKD.
Inhibition of ALP activity TNALP has several inhibitor binding sites 176 and this knowledge has fuelled the development of several pharmacological inhibitors 70, [177] [178] [179] [180] [181] . Most therapeutic strategies aimed at inhibiting ectopic mineralization are flawed by the risk of undesirable inhibition of skeletal mineralization. A novel direct ALP inhibitor, SBI-425, effectively inhibits vascular calcification in animal models at doses that do not alter bone mineralization 70 . This agent is an interesting compound for further development and application in human studies.
Modulation of ALP expression
A different approach to prevent cardiovascular complications in patients with renal diseases is the epigenetic modulation of TNALP expression. The novel bromodomain and extra-terminal motif inhibitor RVX-208 (also known as apabetalone) modulates the epigenetic regulation of several genes 182 . This inhibitor, which was developed for the treatment of atherosclerosis, increases circulating levels of apolipoprotein A-I and high-density lipoprotein 183 . Interestingly, two phase II trials showed that apabetalone administration reduced circulating levels of ALP, which was associated with a marked reduction of major cardiovascular events 184, 185 . The mechanism by which apabetalone modulates ALP activity is still unclear. A large phase III study of this compound for the prevention of cardiovascular complications in T2DM is ongoing 186 ).
ALP targeted to mineralization in hypophosphatasia
Hypophosphatasia is a rare hereditary metabolic disease caused by inactivating mutations in ALPL 130 . This disorder manifests as a wide spectrum of mineralization defects, ranging from mild disease with only slight dental abnormality to severe infantile and prenatal forms with high mortality 130 . Although patients with hypophosphatasia often have hyperphosphataemia, this disease is not associated with accelerated vascular calcification. This finding suggests that TNALP is required for vascular calcification, as P i is a strong inducer of vascular calcification 58 . Enzyme-replacement therapy with asfotase α, a recombinant mineral-targeted human TNALP, was recently approved to treat children with severe infantile hypophosphatasia. This therapy has resulted in dramatic improvements in bone mineralization 187 and survival 188 . Vascular calcification is presumably not yet present in these young individuals; however, long-term administration of asfotase α, especially in the presence of hyperphosphataemia, needs to be carefully monitored, as it could theoretically promote accelerated vascular calcification and resulting cardiovascular complications.
Targeting IALP
IALP supplementation prevented the development of features of the metabolic syndrome in mice fed a high fat-diet 109 . These findings suggest that oral IALP supplementation could represent a novel prevention and treatment strategy for metabolic syndrome in humans. Clinical studies have shown renoprotective and antiinflammatory effects of bovine IALP in sepsis 189 and in patients undergoing cardiac surgery 190 . A phase I study showed that intravenous administration of a novel recombinant form of human IALP in healthy volunteers was safe and well tolerated 191 . Further clinical studies are needed to elucidate whether IALP could prevent and combat systemic and intestinal inflammation, metabolic syndrome and gut dysbiosis. The traditional herbal remedy curcumin increases the expression of IALP, corrects gut permeability in CKD 192 , and inhibits manifestations of metabolic syndrome 193 . These findings raise the possibility of using nutritional approaches to treat metabolic syndrome, uraemic inflammation and gut dysbiosis via IALP upregulation.
Conclusions
Cardiovascular complications remain the leading cause of increased morbidity and mortality in CKD, T2DM, and ageing. The complexity of the underlying pathophysiological processes advocates for a multidimensional approach to treatment and prevention. Despite the introduction of novel treatment strategies targeting the cardiorenal and bone-vascular axes, the burden of CVD is still high. In view of the robust evidence presented in this Review, we propose that ALP is an evolving treatment target for CVD and metabolic syndrome. Thus, the development of compounds that inhibit TNALP either directly or by epigenetic modulation, is a promising novel approach to the treatment and prevention of cardiovascular complications in a large proportion of the general population.
Vascular calcification and inflammation might both drive the association between high ALP levels and increased mortality. BALP, which exerts its main effect on local calcification inhibitors, increases in the circulation in the setting of extensive vascular calcification. The levels of IALP and liver ALP on the other hand increase as part of an inflammatory defence mechanism. This association of high levels of serum ALP with inflammation might explain why in some cases statistical correction for CRP weakens the association of ALP or BALP with mortality. The development of novel TNALP inhibitors and modulators for the prevention of cardiovascular complications, and the development of systemically administered IALP for the treatment of acute inflammatory disorders are promising approaches to reduce the increased mortality associated with CKD and with features of the metabolic syndrome. 
